Uemura et al., 20151313. Uemura S, Kanbayashi T, Wakasa M, Satake M, Ito W, Shimizu K, et al. Residual effects of zolpidem, triazolam, rilmazafone and placebo in healthy elderly subjects: a randomized double-blind study. Sleep Med. 2015;16(11):1395-402. https://doi.org/10.1016/j.sleep.2015.05.021 https://doi.org/https://doi.org/10.1016/...
|
Zolpidem (5 mg) ´ placebo |
I: 33 (SEM=0.19) C: 32.4 (SEM=0.18) |
No data |
No data |
Boyle et al., 20091414. Boyle J, Danjou P, Alexander R, Calder N, Gargano C, Agrawal N, et al. Tolerability, pharmacokinetics and night-time effects on postural sway and critical flicker fusion of gaboxadol and zolpidem in elderly subjects. Br J Clin Pharmacol. 2009;67(2):180-90. https://doi.org/10.1111/j.1365-2125.2008.03331.x https://doi.org/https://doi.org/10.1111/...
|
Zolpidem (5 mg) ´ placebo |
Zolpidem minus placebo (MD) 1 h 30: -0.53 (-1.20 to 0.14) 4 h: -0.1 (-0.77 to 0.57) 8 h: -0.05 (-0.72 to 0.62) |
No data |
No data |
Hindmarch et al., 20061616. Hindmarch I, Legangneux E, Stanley N, Emegbo S, Dawson J. A double-blind, placebo-controlled investigation of the residual psychomotor and cognitive effects of zolpidem-MR in healthy elderly volunteers. Br J Cli Pharmacol. 2006;62(5):538-45. https://doi.org/10.1111/j.1365-2125.2006.02705.x https://doi.org/https://doi.org/10.1111/...
|
Zolpidem (6.25 mg) and (12.5 mg) ´ placebo |
Zolpidem minus placebo (MD) 6.25 mg: 0.2 (-0.38–0.77) 12.5 mg: -0.44 (-1.02–0.14) Performed 8 h after administration |
Mean deviation (Pixels) (MD) 6.25 mg: -2.55 (-10.53–5.43) 12.5 mg: 4.20 (-3.78–12.18) Mean response time (ms) (MD) 6.25 mg: 19.59 (-113.56–74.39) 12.5 mg: 43.80 (-50.17–137.78) |
Zolpidem minus placebo (DM) CRT - Recognition time (ms) 6.25 mg: -10.60 (-36.75 to 15.56) 12.5 mg: 11.18 (-14.97–37.33) CRT - Motor reaction time (ms) 6.25 mg: 9.16 (-12.51–30.82) 12.5 mg: 2.22 (-23.89–19.44) CRT - Total reaction time 6.25 mg: -1.44 (-35.13–32.26) 12.5 mg: 8.96 (-24.74–42.65) |
Bentué-Ferrer et al., 20031717. Bentué-Ferrer D, Allain H, Tarral A, Gandon J. Effects on postural oscillation and memory functions of a single dose of zolpidem 5 mg, zopiclone 3.75 mg and lormetazepam 1 mg in elderly healthy subjects. A randomized, cross-over, double-blind study versus placebo. Eur J Clin Pharmacol. 2003;59(3):179-88. https://doi.org/10.1007/s00228-003-0591-5 https://doi.org/https://doi.org/10.1007/...
|
Zolpidem (5 mg) ´ placebo |
No data |
Mean (±SEM) (mm) H0: I=11.41 (10.56–12.26) C=11.92 (11.13–12.71) H9: I=14.35 (12.44–16.26) C=12.32 (11.22–13.42) |
No data |
Fairweather et al., 19921818. Fairweather D, Kerr J, Hindmarch I. The effects of acute and repeated doses of zolpidem on subjective sleep, psychomotor performance and cognitive function in elderly volunteers. Eur J Clin Pharmacol. 1992;43(6):597-601. https://doi.org/10.1007/bf02284957 https://doi.org/https://doi.org/10.1007/...
|
Zolpidem (5 mg) and (10 mg) ´ placebo |
No data |
Placebo RMSTE (units) - Mean (SD): Day 1 – Baseline=11.4 (7.4); 10H=13.3 (12.4); 12H=14.0 (11.6); 18H=13.2 (11.2); Day 7 – Baseline=13.8 (14.4); 10H=14.0 (16.3); 12H=15.2 (22.0); 18H=13.7 (12.7). Peripheral stimuli (ms) - Mean (SD): Day 1 – Baseline=0.43 (0.08); 10H=0.45 (0.13); 12H=0.46 (0.08); 18H=0.46 (0.1); Day 7 – Baseline=0.45 (0.1); 10H=0.43 (0.08); 12H=0.44 (0.07); 18H=0.46 (0.11) Zolpidem (5 mg) RMSTE (units) - Mean (SD): Day 1 – Baseline=12.7 (10.4); 10H=12.8 (9.6); 12H=13.4 (9.9); 18H=13.5 (10.2); Day 7 – Baseline=11.7 (9.5); 10H=12.6 (9.6); 12H=12.1 (8.5); 18H=12.1 (10.1). Peripheral stimuli (ms) - Mean (SD): Day 1 – Baseline=0.43 (0.07); 10H=0.43 (0.1); 12H=0.46 (0.1); 18H=0.45 (0.6); Day 7 - Baseline=0.43 (0.07); 10H=0.44 (0.07); 12H=0.45 (0.07); 18H=0.45 (0.06). Zolpidem (10 mg) RMSTE (units) - Mean (SD): Day 1 – Baseline=12.5 (10.8); 10H=13.3 (9.9); 12H=13.2 (9.9); 18H=13.4 (11.9); Day 7 – Baseline=11.5 (8.1); 10H=12.4 (10.1); 12H=12.7 (11.3); 18H=13.5 (12.1). Peripheral stimuli (ms) - Mean (SD): Day 1 – Baseline=0.43 (0.08); 10H=0.44 (0.07); 12H=0.46 (0.08); 18H=0.45 (0.08); Day 7 – Baseline=0.44 (0.08); 10H=0.44 (0.08); 12H=0.45 (0.07); 18H=0.46 (0.09). |
“There was no statistically significant difference.” |
Uemura et al., 20151313. Uemura S, Kanbayashi T, Wakasa M, Satake M, Ito W, Shimizu K, et al. Residual effects of zolpidem, triazolam, rilmazafone and placebo in healthy elderly subjects: a randomized double-blind study. Sleep Med. 2015;16(11):1395-402. https://doi.org/10.1016/j.sleep.2015.05.021 https://doi.org/https://doi.org/10.1016/...
|
No data |
Accuracy rate (%) I: 94.2 (SEM=1.1) C: 92.9 (SEM=0.9) Reaction time (s) I: 0.51 (0.01) C: 0.5 (0.01) |
I: Accuracy rate (%)=34.6 (2.4) C: Accuracy rate (%)=32.1 (2.4) |
No data |
No data |
No data |
No data |
No data |
Boyle et al., 20091414. Boyle J, Danjou P, Alexander R, Calder N, Gargano C, Agrawal N, et al. Tolerability, pharmacokinetics and night-time effects on postural sway and critical flicker fusion of gaboxadol and zolpidem in elderly subjects. Br J Clin Pharmacol. 2009;67(2):180-90. https://doi.org/10.1111/j.1365-2125.2008.03331.x https://doi.org/https://doi.org/10.1111/...
|
No data |
No data |
No data |
No data |
No data |
No data |
No data |
No data |
Hindmarch et al., 20061616. Hindmarch I, Legangneux E, Stanley N, Emegbo S, Dawson J. A double-blind, placebo-controlled investigation of the residual psychomotor and cognitive effects of zolpidem-MR in healthy elderly volunteers. Br J Cli Pharmacol. 2006;62(5):538-45. https://doi.org/10.1111/j.1365-2125.2006.02705.x https://doi.org/https://doi.org/10.1111/...
|
No data |
No data |
No data |
Zolpidem minus placebo (MD) (nº) 6.25 mg: 0.68 (-1.24–2.61) 12.5 mg: 0.73 (-1.2–2.65) |
No data |
No data |
No data |
Zolpidem minus placebo (MD) (nº) Immediate word recall 6.25 mg: -0.34 (-1.47–0.78) 12.5 mg: -0.68 (-1.8–0.45) Delayed word recall 6.25 mg: -0.08 (-1.29–1.13) 12.5 mg: -1.05 (-2.26–0.16) |
Bentué-Ferrer et al., 20031717. Bentué-Ferrer D, Allain H, Tarral A, Gandon J. Effects on postural oscillation and memory functions of a single dose of zolpidem 5 mg, zopiclone 3.75 mg and lormetazepam 1 mg in elderly healthy subjects. A randomized, cross-over, double-blind study versus placebo. Eur J Clin Pharmacol. 2003;59(3):179-88. https://doi.org/10.1007/s00228-003-0591-5 https://doi.org/https://doi.org/10.1007/...
|
Mean (SEM) 2 digits H0: I=825 (42) C=985 (62) H9: I=892 (40) C=923 (56) 3 digits H0: I=926 (34) C=953 (45) H9: I=933 (33) C=950 (44) 4 digits H0: I=982 (39) C=995 (39) H9: I=950 (34) C=997 (41) 5 digits H0: I=1027 (39) C=1073 (50) H9: I=1010 (34) C=1039 (42) 6 digits H0: I=1123 (64) C=1136 (63) H9: I=1084 (41) C=1052 (36) |
No data |
No data |
No data |
IFRL (H9) (nº) I: 5 (mean) C: 4 (mean) MFIR (H9) (nº) I: 7 (mean) C: 7 (mean) DFR (H10) (nº) I: 6 (mean) C: 6 (mean) |
Mean (±SEM) (ms) H0: I=344.97 (305.37–384.57) C=320.61 (308.21–333.01) H4: I=323.45 (315.05–331.85) C=338.29 (328.29–348.29) H5: I=335.13 (325.53–344.73) C=345.17 (333.17–357.17) H6: I=345.62 (333.62–357.62) C=347.65 (335.65–359.65) H8: I=336.50 (324.90–348.10) C=354.13 (340.53–367.73) H10: I=316.57 (310.17–322.97) C=331.00 (319.40–342.60) |
No data |
No data |
Fairweather et al., 19921818. Fairweather D, Kerr J, Hindmarch I. The effects of acute and repeated doses of zolpidem on subjective sleep, psychomotor performance and cognitive function in elderly volunteers. Eur J Clin Pharmacol. 1992;43(6):597-601. https://doi.org/10.1007/bf02284957 https://doi.org/https://doi.org/10.1007/...
|
“There was no statistically significant difference.” |
No data |
No data |
No data |
No data |
No data |
“There was no statistically significant difference.” |
No data |